US Stock MarketDetailed Quotes

AVPT AvePoint

Watchlist

17.760
-0.650-3.53%

Close Dec 18 16:00 ET

17.760
0.0000.00%

Pre 06:57 ET

3.33BMarket Cap-355.20P/E (TTM)

AvePoint Stock Forum

Iwill TradeScared

Jul 9 18:38

$AvePoint (AVPT.US)$ 👀 above 10.50 may run to 18$

Macdaryl

May 13, 2022 09:46

$AvePoint (AVPT.US)$ should have sold this prior to merger 🤣

Moomoo Breakfast US

Mar 21, 2022 07:26

Columns Today's pre-market stock movers: PLAN, IMGN, NLSN and more

Gainers
• $Anaplan (PLAN.US)$ +28.2% (to be acquired by Thoma Bravo for $66.00 per share)
• $Guess (GES.US)$ +5.04% (entered into an accelerated share repurchase agreement to repurchase $175 mln of its common stock)
• $Membership Collective (MCG.US)$ +2.8% (authorizes stock repurchase program to repurchase up to $50 mln of the Company's Class A common stock)
• $Sorrento Therapeutics (SRNE.US)$ +2.3% (reports promising results with a universal...

Analysts Notebook

Mar 21, 2022 06:10

Columns Top upgrades and downgrades on 3/21

Upgrades
• $Air Products & Chemicals (APD.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $275
• $Associated Banc (ASB.US)$: Wells Fargo Upgrades to Overweight from Equal Weight - PT $28 (from $26)
• $Armstrong World Industries (AWI.US)$: Jefferies Upgrades to Buy from Hold - PT $111 (from $101)
• $BlackBerry (BB.US)$: RBC Capital Upgrades to Sector Perform from Underperform - PT $7
• $Commerce Bancshares (CBSH.US)$: Wells Fargo Upgrades to Equal Weight from...

Geertruida

Nov 26, 2021 04:18

Which Biotech Stocks would profit from New ‘Nu’ COVID Strain

$Microsoft (MSFT.US)$ $AvePoint (AVPT.US)$
From what we know the new strain seems more resistant against existing vaccines. That would suggest that we need new vaccines to address this new variant.
How could we translate this hypothesis into a stock position?
I’m not familiar with the pharma industry and don’t know how things work in pharma. But from what I know you usually have small startups innovating and coming up with vaccine technologies and then larger corporations acquiring them.
So how would we expect biotech stocks to behave as the new COVID strain becomes priced into the market?